Becton, Dickinson and Company to Post Q1 2019 Earnings of $3.04 Per Share, Jefferies Group Forecasts (BDX)

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Jefferies Group issued their Q1 2019 earnings per share (EPS) estimates for shares of Becton, Dickinson and in a note issued to investors on Thursday. Jefferies Group analyst B. Couillard expects that the medical instruments supplier will earn $3.04 per share for the quarter. Jefferies Group also issued estimates for Becton, Dickinson and’s Q2 2019 earnings at $2.96 EPS, Q3 2019 earnings at $3.25 EPS and Q4 2019 earnings at $3.25 EPS.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. Becton, Dickinson and’s revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.12 earnings per share. TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/becton-dickinson-and-company-to-post-q1-2019-earnings-of-3-04-per-share-jefferies-group-forecasts-bdx.html.

Several other research firms have also weighed in on BDX. Wells Fargo & Company reissued a “positive” rating and issued a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Morgan Stanley upped their target price on Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Bank of America Corporation reissued a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $213.47.

Becton, Dickinson and (NYSE BDX) opened at $219.23 on Friday. The stock has a market capitalization of $49,889.07, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. Becton, Dickinson and has a 52-week low of $161.29 and a 52-week high of $225.23.

Large investors have recently modified their holdings of the business. Almanack Investment Partners LLC. acquired a new stake in Becton, Dickinson and in the 1st quarter worth about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the period. Parkside Financial Bank & Trust raised its holdings in shares of Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 51 shares during the period. Harfst & Associates Inc. raised its holdings in shares of Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the period. Finally, Financial Architects Inc raised its holdings in shares of Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after purchasing an additional 54 shares during the period. 86.71% of the stock is currently owned by hedge funds and other institutional investors.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stephen Sichak sold 11,787 shares of the firm’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the sale, the insider now directly owns 14,038 shares in the company, valued at $2,814,057.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,650 shares of company stock worth $12,223,970. Corporate insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply